Pulmonary Vascular Disease: Pulmonary Vascular Disease II |

Multiple Pathway Modulating Therapy for Pulmonary Hypertension: A Survey of Practice Patterns and Perceptions FREE TO VIEW

Jesslyn Magee, BS; Andrea Gochi, BA; Vivek Gupta, PhD
Author and Funding Information

School of Applied Life Sciences, Keck Graduate Institute, Claremont, CA

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;150(4_S):1186A. doi:10.1016/j.chest.2016.08.1295
Text Size: A A A
Published online

SESSION TITLE: Pulmonary Vascular Disease II

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: Pulmonary hypertension (PH) is a rare, life-threatening disease that is commonly associated with various comorbidities. Although multiple therapies are approved by FDA in recent years, less than significant improvement is seen in patient survival. A primary reason for suboptimal therapeutic benefits can be attributed to ability of current therapies to merely ameliorate PH symptoms without limiting the vasculopathy associated with disease progression. Due to existence of overlapping and interconnected pathological pathways, PH management has been a cumbersome task as the current therapeutic interventions only target one of the many pathological pathways involved. This study is aimed to evaluate the need for a multiple pathway modulating therapy for PH management.

METHODS: To assess the need for multiple pathway modulating therapy, a survey was designed and distributed to PH clinicians and experts. The survey contained a total of 10 questions on a Likert scale of 1-5, and focused on issues surrounding current PH therapies: efficacy, safety, patient compliance and the need for a therapy modulating multiple pathways. Quantitative and qualitative responses were recorded, and the obtained data were analyzed.

RESULTS: Preliminary results of the study showed that there was unanimous acceptance among PH healthcare professionals of the need for a therapy modulating multiple pathways (overall numeric response being 5 on a scale of 1-5). Furthermore, the current therapies were only moderately successful in terms of patient compliance (3 on a scale of 1-5). In addition to the issues with patient compliance and need for multiple pathway modulating therapy, it was also discovered that there are tremendous cost implications of PH treatment on payers. Based on preliminary calculations, a new therapy modulating multiple pathogenic pathways will minimize the number of prescription medications and mitigate re-hospitalization occurrences, thus saving each patient upwards of $150,000.

CONCLUSIONS: Overall, we found that in consideration of disease outcome and cost burden of PH, there is great potential for a new multiple pathway modulating therapy to be successful in the PH market.

CLINICAL IMPLICATIONS: Clinical implications of developing a novel therapy capable of modulating multiple pathogenic pathways responsible for PH pathogenesis will be beneficial in not only advancing the current PH therapeutic regimen but will also have significant benefits in elucidating and exploiting the pathological links between PH and several associated disorders.

DISCLOSURE: The following authors have nothing to disclose: Jesslyn Magee, Andrea Gochi, Vivek Gupta

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543